H. Lundbeck 将来の成長
Future 基準チェック /06
H. Lundbeckの収益と利益は、それぞれ年間3.3%と4.9%減少すると予測されています。EPS は年間3.9%で 減少すると予想されています。自己資本利益率は 3 年後に13.1%になると予測されています。
主要情報
-4.9%
収益成長率
-3.88%
EPS成長率
| Pharmaceuticals 収益成長 | 10.6% |
| 収益成長率 | -3.3% |
| 将来の株主資本利益率 | 13.06% |
| アナリストカバレッジ | Good |
| 最終更新日 | 10 Jul 2026 |
今後の成長に関する最新情報
分析記事 • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...分析記事 • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...分析記事 • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...Recent updates
ナラティブの更新 • Jun 22
HLUN B: Neuroscience Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their fair value estimate for H. Lundbeck at DKK 47.21.分析記事 • Jun 18
H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data
H. Lundbeck (CPSE:HLUN B) stock is in focus after the company reported preliminary Phase II Part A data for asedebart in Cushing's disease, showing urinary free cortisol normalization in most evaluable patients. See our latest analysis for H. Lundbeck. The preliminary asedebart data arrives after a steady run in H. Lundbeck's stock, with the latest share price at DKK42.32, a 30 day share price return of 5.43% and a 90 day share price return of 13.95%, while the 1 year total shareholder return...
ナラティブの更新 • Jun 06
HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple
Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.分析記事 • May 24
H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively
H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...ナラティブの更新 • May 23
HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside
Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.分析記事 • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
ナラティブの更新 • May 05
HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins
Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.ナラティブの更新 • Apr 20
HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook
Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.ナラティブの更新 • Apr 05
HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins
Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.ナラティブの更新 • Mar 22
HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion
Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.ナラティブの更新 • Mar 08
HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential
Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.ナラティブの更新 • Feb 22
HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook
Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.ナラティブの更新 • Feb 08
HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares
Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.分析記事 • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...ナラティブの更新 • Jan 25
HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook
Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.分析記事 • Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...ナラティブの更新 • Jan 11
HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook
Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.ナラティブの更新 • Dec 27
HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements
Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.ナラティブの更新 • Dec 13
HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares
Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.分析記事 • Nov 22
The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business
H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...分析記事 • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • Oct 28
Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)
With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...ナラティブの更新 • Sep 05
CNS Pipeline And Global Expansion Will Unlock Future Opportunities
With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.分析記事 • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...
新しいナラティブ • Dec 04
Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth
Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 25,051 | 4,270 | 5,476 | 6,034 | 10 |
| 12/31/2027 | 25,879 | 4,597 | 6,175 | 6,824 | 11 |
| 12/31/2026 | 25,773 | 4,553 | 5,663 | 6,289 | 11 |
| 3/31/2026 | 25,520 | 3,730 | 4,825 | 5,448 | N/A |
| 12/31/2025 | 24,630 | 3,192 | 4,863 | 5,481 | N/A |
| 9/30/2025 | 24,078 | 3,777 | 2,778 | 3,406 | N/A |
| 6/30/2025 | 23,521 | 3,453 | 2,851 | 3,409 | N/A |
| 3/31/2025 | 22,951 | 3,257 | 2,415 | 2,997 | N/A |
| 12/31/2024 | 22,004 | 3,143 | 2,761 | 3,326 | N/A |
| 9/30/2024 | 21,441 | 2,687 | 4,936 | 5,421 | N/A |
| 6/30/2024 | 20,671 | 2,586 | 4,128 | 4,609 | N/A |
| 3/31/2024 | 20,156 | 2,416 | 4,145 | 4,663 | N/A |
| 12/31/2023 | 19,912 | 2,290 | 3,579 | 4,080 | N/A |
| 9/30/2023 | 19,614 | 2,467 | 3,528 | 4,426 | N/A |
| 6/30/2023 | 19,381 | 2,479 | 3,523 | 4,457 | N/A |
| 3/31/2023 | 18,918 | 2,384 | 3,292 | 4,102 | N/A |
| 12/31/2022 | 18,246 | 1,916 | 2,699 | 3,519 | N/A |
| 9/30/2022 | 17,619 | 1,603 | 2,051 | 2,615 | N/A |
| 6/30/2022 | 16,913 | 1,236 | 1,744 | 2,313 | N/A |
| 3/31/2022 | 16,398 | 1,109 | 1,344 | 1,959 | N/A |
| 12/31/2021 | 16,299 | 1,318 | 1,660 | 2,272 | N/A |
| 9/30/2021 | 16,521 | 1,873 | 2,405 | 2,949 | N/A |
| 6/30/2021 | 16,971 | 1,965 | 2,379 | 2,912 | N/A |
| 3/31/2021 | 17,381 | 2,110 | 3,263 | 3,757 | N/A |
| 12/31/2020 | 17,672 | 1,581 | 3,359 | 3,837 | N/A |
| 9/30/2020 | 17,818 | 904 | 2,713 | 3,171 | N/A |
| 6/30/2020 | 17,490 | 1,242 | 2,910 | 3,354 | N/A |
| 3/31/2020 | 17,366 | 1,507 | 1,502 | 1,960 | N/A |
| 12/31/2019 | 17,036 | 2,313 | N/A | 2,609 | N/A |
| 9/30/2019 | 16,811 | 3,091 | N/A | 3,621 | N/A |
| 6/30/2019 | 17,309 | 3,395 | N/A | 3,462 | N/A |
| 3/31/2019 | 17,766 | 3,606 | N/A | 4,815 | N/A |
| 12/31/2018 | 18,117 | 3,907 | N/A | 5,981 | N/A |
| 9/30/2018 | 18,313 | 3,806 | N/A | 5,922 | N/A |
| 6/30/2018 | 18,028 | 3,627 | N/A | 6,197 | N/A |
| 3/31/2018 | 17,608 | 3,236 | N/A | 5,397 | N/A |
| 12/31/2017 | 17,234 | 2,624 | N/A | 4,045 | N/A |
| 9/30/2017 | 17,007 | 2,544 | N/A | 3,731 | N/A |
| 6/30/2017 | 16,607 | 1,988 | N/A | 3,551 | N/A |
| 3/31/2017 | 16,075 | 1,612 | N/A | 3,420 | N/A |
| 12/31/2016 | 15,634 | 1,211 | N/A | 3,126 | N/A |
| 9/30/2016 | 15,202 | 290 | N/A | 4,158 | N/A |
| 6/30/2016 | 14,923 | -1,289 | N/A | 2,755 | N/A |
| 3/31/2016 | 14,801 | -5,427 | N/A | 936 | N/A |
| 12/31/2015 | 14,594 | -5,694 | N/A | 197 | N/A |
| 9/30/2015 | 14,108 | -5,879 | N/A | -1,330 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: HLUN Bの収益は今後 3 年間で減少すると予測されています (年間-4.9% )。
収益対市場: HLUN Bの収益は今後 3 年間で減少すると予測されています (年間-4.9% )。
高成長収益: HLUN Bの収益は今後 3 年間で減少すると予測されています。
収益対市場: HLUN Bの収益は今後 3 年間で減少すると予想されています (年間-3.3% )。
高い収益成長: HLUN Bの収益は今後 3 年間で減少すると予測されています (年間-3.3% )。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: HLUN Bの 自己資本利益率 は、3年後には低くなると予測されています ( 13.1 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/12 22:01 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
H. Lundbeck A/S 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。34
| アナリスト | 機関 |
|---|---|
| Rosie Turner | Barclays |
| Charles Pitman | Barclays |
| Emily Field | Barclays |